Keyphrases
Chemotherapy
42%
Ovarian Cancer
36%
Platinum-resistant Ovarian Cancer
33%
Cervical Cancer
32%
Progression-free Survival
31%
Carboplatin
28%
Placebo
26%
Platinum Resistance
25%
Carbohydrate Antigen 125 (CA125)
23%
ENGOT
23%
Phase II Study
22%
Overall Survival
21%
Paclitaxel
19%
Randomized Phase II Trial
19%
Dostarlimab
18%
Objective Response Rate
18%
Invasive Cervical Cancer
18%
Endometrial Cancer
16%
Ovarian Cancer Patients
15%
Advanced Ovarian Cancer
15%
Confidence Interval
15%
Locally Advanced Cervical Cancer
14%
Garnet
14%
Clinical Calculator
14%
Ipilimumab
14%
Randomized Placebo-controlled Trial
14%
Atezolizumab
14%
Phase II Trial
14%
Serum Proteins
13%
Recurrence Rate
12%
Primary Peritoneal Cancer
12%
Cisplatin
11%
Mismatch Repair
11%
Microsatellite Instability-high (MSI-H)
11%
Tolerability
11%
Bevacizumab
10%
Phase I Trial
10%
Antitumor Activity
10%
Neutropenia
10%
Recurrent Ovarian Cancer
10%
First-line Chemotherapy
10%
Randomized Double-blind
10%
High-grade Serous Ovarian Cancer (HGSOC)
10%
Complete Response
9%
Stable Disease
9%
5-year Survival
9%
Remission
9%
Peritoneal Cancer
9%
Gynecological Cancer
9%
Ovarian Tumor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Uterine Cervix Cancer
44%
Chemotherapy
35%
Carboplatin
33%
Disease
33%
Paclitaxel
31%
Progression Free Survival
30%
Placebo
28%
Recurrent Disease
20%
Plasma Protein
19%
Biological Marker
19%
Overall Survival
18%
Endometrium Cancer
18%
Phase II Trials
16%
Adverse Event
14%
Niraparib
14%
Cisplatin
12%
Neoplasm
12%
Pharmacokinetics
11%
Ovary Carcinoma
11%
Tolerability
11%
Remission
10%
Peritoneum Cancer
10%
First-Line Chemotherapy
9%
Ovary Tumor
9%
Guadecitabine
9%
Chemoradiation Therapy
9%
Modafinil
9%
Ipilimumab
9%
Tisotumab Vedotin
9%
Antitumor Activity
8%
Neutropenia
7%
Doxorubicin
7%
Solid Malignant Neoplasm
7%
Clinical Trial
7%
Immunotherapy
7%
Phase I Trials
6%
Malignant Neoplasm
6%
Bevacizumab
6%
Thrombocytopenia
6%
Topotecan
5%
Carcinoma
5%
Breast Cancer
5%
Anemia
5%
Cyclophosphamide
5%
Medicine and Dentistry
Ovarian Cancer
61%
Disease
29%
Progression Free Survival
26%
Placebo
24%
Cervical Cancer
24%
Carboplatin
23%
Overall Survival
20%
Malignant Neoplasm
19%
Paclitaxel
18%
Recurrent Ovarian Cancer
16%
Arm
16%
Recurrent Disease
16%
Phase II Trials
15%
Clinical Trial
15%
Platinum-Resistant Ovarian Cancer
15%
Pelvis
13%
Endometrial Cancer
12%
Neoplasm
11%
Biological Marker
11%
CA-125
11%
Fallopian Tube
11%
Adverse Event
10%
Female Genital Tract Cancer
10%
BRCA1
10%
Peritoneum Cancer
9%
Guadecitabine
9%
Cervix
9%
Ipilimumab
9%
Krukenberg Tumor
8%
Immunotherapy
7%
Adenocarcinoma
7%
DNA Mismatch Repair
6%
Microsatellite Instability
6%
Primary Peritoneal Cancer
6%
Antineoplastic Activity
6%
Cyclophosphamide
6%
Minimal Residual Disease
6%
Adjuvant Chemotherapy
6%
Gynecological Oncology
5%
Neutropenia
5%
Second Trimester Pregnancy
5%
Bevacizumab
5%
Maintenance Therapy
5%
High Risk Population
5%
Topotecan
5%
Serum Total Protein
5%
Monotherapy
5%
Pharmacokinetics
5%
Immunohistochemistry
5%
Sensitization
5%